ABSTRACT
Atopic dermatitis (AD) is a persistent skin disease typified by symptoms of dry skin and recurrent eczema. Patients with AD are at heightened risk for Staphylococcus aureus infection. Group 2 innate lymphoid cells (ILC2s) are mainly activated by epithelial cell-derived cytokines IL-33 and involved in the pathogenesis of AD. However, little is known about the effect of skin delipidization on the epithelial cell-derived cytokines and dermal ILC2s in AD. In our study, we investigated the mechanism by which S. aureus infection modulates and exacerbates the pathogenesis of dry skin, leading to type 2 inflammation in the context of innate immunity. In vivo, we found that S. aureus infection aggravated delipidization-induced dermal IL-33 release and dermal ILC2 accumulation, which exacerbated skin inflammation. We also noticed that Il33fl/fl K14cre mice and Tlr2-/- mice exhibited attenuated skin inflammation. In vitro, treatment with necroptosis inhibitors reduced IL-33 release from S. aureus-infected keratinocytes. Mechanistically, we observed an increase in the necroptosis-associated kinases, MLKL and RIPK3, in S. aureus-infected mice, indicating that IL-33 release was associated with necroptotic cell death responses. Our results reveal that S. aureus infection-elicited keratinocyte necroptosis contributes to IL-33-mediated type 2 inflammation, which exacerbates the pathogenesis of dry skin.
Subject(s)
Dermatitis, Atopic , Ichthyosis , Staphylococcal Infections , Humans , Mice , Animals , Immunity, Innate , Staphylococcus aureus , Interleukin-33/metabolism , Necroptosis , Lymphocytes , Inflammation/pathology , Cytokines/metabolism , Receptor-Interacting Protein Serine-Threonine Kinases/metabolism , Protein Kinases/metabolismABSTRACT
In this study, we selected bacteremic Klebsiella pneumoniae isolates from the Taiwan Surveillance of Antimicrobial Resistance program. A total of 521 isolates were collected over a period of 2 decades, including 121 from 1998, 197 from 2008, and 203 from 2018. Seroepidemiology showed that the top five capsular polysaccharide types were serotypes K1, K2, K20, K54, and K62, constituting 48.5% of the total isolates, and the respective ratios at each time point have remained similar over the past 2 decades. The antibacterial susceptibility tests showed that K1, K2, K20, and K54 were susceptible to most antibiotics, while K62 was relatively resistant compared to other typeable and nontypeable strains. In addition, six virulence-associated genes, clbA, entB, iroN, rmpA, iutA, and iucA, were predominant in K1 and K2 isolates of K. pneumoniae. In conclusion, serotypes K1, K2, K20, K54, and K62 of K. pneumoniae are the most prevalent serotypes and carry more virulence determinants in bacteremia patients, which may indicate their invasiveness. If further serotype-specific vaccine development is performed, these five serotypes should be included. Since the antibiotic susceptibility profiles were stable over a long duration, empirical treatment may be predicted according to serotype if rapid diagnosis from direct clinical specimens is available, such as PCR or antigen serotyping for serotype K1 and K2. IMPORTANCE This is the first nationwide study to examine the seroepidemiology of Klebsiella pneumoniae using blood culture isolates collected over a period of 20 years. The study found that the prevalence of serotypes remained consistent over the 20-year period, with high-prevalence serotypes associated with invasive types. Nontypeable isolates had fewer virulence determinants than other serotypes. With the exception of serotype K62, the other high-prevalence serotypes were highly susceptible to antibiotics. If rapid diagnosis using direct clinical specimens, such as PCR or antigen serotyping, is available, empirical treatment can be predicted based on serotype, particularly for K1 and K2. The results of this seroepidemiology study could also help the development of future capsule polysaccharide vaccines.
Subject(s)
Bacteremia , Klebsiella Infections , Humans , Virulence/genetics , Klebsiella pneumoniae , Taiwan/epidemiology , Seroepidemiologic Studies , Virulence Factors/genetics , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Polysaccharides , Bacteremia/epidemiology , Bacteremia/drug therapy , Klebsiella Infections/microbiologyABSTRACT
BACKGROUND/PURPOSE: Clinical characteristics of patients in the first community outbreak of coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 in Taiwan have not been characterized. METHODS: SARS-CoV-2 positive specimens from inpatients between May 7 and June 15 in 2021were screen for SARS-CoV-2 B.1.1.7 lineage by VirSNiP assay. Clinical characteristics were reviewed and compared with those from Feb 1 to April 30, 2020 and from Jan 1 to March 31, 2022. RESULTS: One hundred forty-one inpatients from May 7 to June 15, 2021 infected with SARS-CoV-2 B.1.1.7 lineage were included. The major presenting symptoms were fever (88.7%) and cough (59.6%). Incidence of relevant complications including pulmonary embolism, simultaneous infections with bacteria, virus, and fungi were 0.7%, 12.8%, 13.5%, and 2.1%, respectively. Old age, high Charlson comorbidity index, short of breath, and initial critical illness were independently associated with 28-day mortality (all p < 0.05). In comparison to COVID-19 inpatients from Feb 1 to April 30, 2020, patients from the outbreak by SARS-CoV-2 B.1.1.7 lineage were older, more severe in disease condition, higher mortality but less obvious initial presenting symptoms. After implementation of nationwide vaccination campaign in the next half year of 2021, COVID-19 inpatients from Jan 1 to March 31 in 2022 indicated less severe diseases than those infected with SARS-CoV-2 B.1.1.7 lineage. CONCLUSION: COVID-19 inpatients by SARS-CoV-2 variant B.1.1.7 with old age, multiple comorbidities, and more severe disease conditions were associated with increased mortality. Vaccination for this vulnerable populations may be helpful.
Subject(s)
COVID-19 , SARS-CoV-2 , Humans , SARS-CoV-2/genetics , COVID-19/diagnosis , COVID-19/epidemiology , Taiwan/epidemiology , Disease OutbreaksABSTRACT
BACKGROUND: Coronavirus disease 2019 (COVID-19) inpatients may acquire infections from other pathogens during hospital admission. This is the first research on this subject to be reported from Taiwan. METHODS: Confirmed COVID-19 inpatients were enrolled in this study from January 1, 2020 to July 31, 2021. Various types of pathogens in COVID-19 inpatients, with hospital-acquired infections, were identified and analyzed. The clinical characteristics of COVID-19 patients with and without hospital-acquired infections were reviewed and compared. RESULTS: Of the 204 patients included in the study, 32 (15.7%) patients experienced at least one infectious episode. Of 113 recorded episodes of infection, the predominant type was bacterial (88 of 113 infections, 77.9%); the most frequently isolated bacteria were Acinetobacter spp., followed by Stenotrophomonas maltophilia . With regard to viral infections (19 of 113, 16.8%), the Epstein-Barr virus ranked first place among the identified viruses. Four (3.5%) and 2 (1.8%) of 113 infectious episodes were caused by fungi and atypical pathogens. A multivariate analysis revealed that steroid use was an independent factor in hospital-acquired infections (odds ratio [OR], 6.97; 95% confidence interval [CI], 1.15-42.43; p = 0.035). Patients with hospital-acquired infections were associated with increased 28-day and in-hospital mortality (18.8% vs 5.8% and 31.3% and 5.8%; p = 0.023 and <0.01, respectively), and a longer hospital stay (34 vs 19 days; p < 0.001), compared to those without hospital-acquired infections. CONCLUSION: Our study revealed the unique local epidemiology of hospital-acquired infections among COVID-19 inpatients in Taiwan. These patients were associated with increased mortality and prolonged hospital admissions.
Subject(s)
COVID-19 , Cross Infection , Epstein-Barr Virus Infections , Cross Infection/epidemiology , Herpesvirus 4, Human , Hospitals , Humans , Retrospective Studies , Steroids , Taiwan/epidemiologyABSTRACT
BACKGROUND: Coronavirus disease-2019 (COVID-19) is a worldwide pandemic. We present the clinical characteristics and outcomes of 28 COVID-19 patients treated in our hospital in Taiwan. METHODS: Patients with COVID-19, confirmed by positive real-time reverse-transcriptase polymerase chain reaction results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral nucleic acids from oropharyngeal swab specimens between February 4, 2020 and July 6, 2020, were enrolled. Their clinical characteristics and outcomes were reviewed. RESULTS: Seventeen of the 28 patients (60.7%) had pneumonia. The most frequent symptoms were cough (n = 23, 82.1%) and fever (n = 17, 60.7%). The development of pneumonia was associated with age ≥40 years (p < 0.024), body mass index (BMI) ≥25 kg/m2 (p = 0.014), fever (p = 0.007), shortness of breath (p = 0.036), chills ((p = 0.047), and lower platelet counts (<200,000/µL) (p = 0.007). Increased quarantine duration was associated with age ≥40 years (p = 0.026), Charlson index ≥1 (p = 0.037), lower lymphocyte (<1500/uL; p = 0.028) or platelet counts (<200,000/µL) (p = 0.016), lower serum sodium (<140 mEq/L; p = 0.006), and higher C-reactive protein (CRP) level (≥1 mg/dl; p = 0.04). Treatment with hydroxychloroquine or in combination with other medicines did not reduce the quarantine duration. All 28 patients recovered with a median quarantine duration of 27.2 days. CONCLUSION: COVID-19 patients with older age, higher BMI, fever, chills or shortness of breath, lower serum sodium level, lower platelet or lymphocyte count, and higher CRP level may be associated with developing pneumonia or longer quarantine duration.
Subject(s)
COVID-19 Nucleic Acid Testing/methods , COVID-19 , Pneumonia, Viral , SARS-CoV-2/isolation & purification , Adult , Age Factors , Blood Cell Count/methods , Body Mass Index , C-Reactive Protein/analysis , COVID-19/blood , COVID-19/epidemiology , COVID-19/physiopathology , COVID-19/therapy , Female , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Outcome Assessment, Health Care , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/etiology , Quarantine , Risk Factors , Symptom Assessment/methods , Taiwan/epidemiologySubject(s)
Blindness/diagnosis , HIV Infections/complications , Syphilis/complications , Administration, Intravenous , Adult , Anti-HIV Agents/therapeutic use , Coinfection , HIV Infections/drug therapy , Humans , Male , Neurologic Examination , Ophthalmoscopy , Paresis/etiology , Penicillin G/administration & dosage , Penicillin G/therapeutic use , Syphilis/diagnosis , Syphilis/drug therapy , Syphilis Serodiagnosis , Treatment OutcomeSubject(s)
Complement System Proteins/deficiency , Epstein-Barr Virus Infections/complications , Respiratory Distress Syndrome/virology , Urticaria/immunology , Vasculitis/immunology , Early Diagnosis , Humans , Male , Middle Aged , Respiratory Distress Syndrome/diagnostic imaging , Tomography, X-Ray Computed , Urticaria/virology , Vasculitis/virologyABSTRACT
Mounting evidence suggests a connection between human parvovirus B19 (B19) and autoimmune diseases, and especially an association between the B19-VP1 unique region (VP1u) and anti-phospholipid syndrome (APS). However, little is known about the antigenicity of B19-VP1u in the induction of APS-like syndrome. To elucidate the antigenicity of B19-VP1u in the induction of APS, N-terminal truncated B19-VP1u (tVP1u) proteins were prepared to immunize Balb/c mice to generate antibodies against B19-tVP1u proteins. The secreted phospholipase A2 (sPLA2) activities and binding specificity of mice anti-B19-tVP1u antibodies with cardiolipin (CL) and beta-2-glycoprotein I (ß2GPI) were evaluated by performing immunoblot, ELISA and absorption experiments. A mice model of passively induced APS was adopted. Although sPLA2 activities were identified in all B19-tVP1u proteins, only amino acid residues 61-227 B19-tVP1u exhibited a higher sPLA2 activity. Autoantibodies against CL and ß2GPI exhibited binding activities with all B19-tVP1u proteins. IgG that was purified from mice that had been immunized with amino acid residues 21-227 to 121-227 B19-tVP1u proteins exhibited significantly higher binding activity with CL. IgG that was purified from mice that had been immunized with amino acid residues 21-227, 31-227, 82-227 and 91-227 B19-tVP1u proteins exhibited significantly higher binding activity with ß2GPI. Accordingly, significantly higher binding inhibition of CL was detected in the presence of amino acid residues 61-227 and 101-227 B19-tVP1u. Significantly higher binding inhibition of ß2GPI was detected in the presence of amino acid residues 21-227, 31-227, 82-227 and 91-227 B19-tVP1u. The mice that received amino acid residues 31-227 or 61-227 anti-tB19-VP1u IgG revealed significant thrombocytopenia and those that received amino acid residues 21-227, 31-227, 61-227, 71-227, 82-227, 91-227, 101-227 or 114-227 anti-tB19-VP1u IgG exhibited significantly prolonged aPTT. These findings provide further information concerning the role of B19-VP1u antigenicity in APS-like autoimmunity.
Subject(s)
Antiphospholipid Syndrome/immunology , Capsid Proteins/chemistry , Capsid Proteins/immunology , Parvovirus B19, Human/immunology , Animals , Autoantigens/metabolism , Capsid Proteins/antagonists & inhibitors , Cardiolipins/metabolism , Disease Models, Animal , Female , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoglobulin G/metabolism , Mice , Mice, Inbred BALB C , Phospholipases A2, Secretory/analysis , Protein Binding , beta 2-Glycoprotein I/metabolismABSTRACT
Atopic dermatitis is a complex chronic inflammatory skin disorder that results from intimate interactions among genetic predisposition, host environment, skin barrier defects, and immunological factors. However, a clear genetic roadmap leading to atopic dermatitis remains to be fully explored. From a genome-wide mutagenesis screen, deficiency of ZDHHC13, a palmitoylacyl transferase, has previously been associated with skin and multitissue inflammatory phenotypes. Here, we report that ZDHHC13 is required for skin barrier integrity and that deficiency of ZDHHC13 renders mice susceptible to environmental bacteria, resulting in persistent skin inflammation and an atopic dermatitis-like disease. This phenotype is ameliorated in a germ-free environment and is also attenuated by antibiotic treatment, but not by deletion of the Rag1 gene, suggesting that a microbial factor triggers inflammation rather than intrinsic adaptive immunity. Furthermore, skin from ZDHHC13-deficient mice has both elevated levels of IL-33 and type 2 innate lymphoid cells, reinforcing the role of innate immunity in the development of atopic dermatitis. In summary, our study suggests that loss of ZDHHC13 in skin impairs the integrity of multiple barrier functions and leads to a dermatitis lesion in response to microbial encounters.
Subject(s)
Acyltransferases/genetics , Cytokines/metabolism , Dermatitis, Atopic/genetics , Dermatitis, Atopic/immunology , Dermatitis/microbiology , Immunity, Innate/genetics , Animals , Biomarkers/analysis , Biopsy, Needle , Cytokines/immunology , Dermatitis/pathology , Dermatitis, Atopic/pathology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation , Humans , Immunohistochemistry , Lipoylation/genetics , Mice , Mice, Mutant Strains , Random Allocation , Real-Time Polymerase Chain ReactionABSTRACT
Lactoferrin (LF) has beneficial effects against various diseases. However, the effects of LF on liver fibrosis in systematic lupus erythematosus (SLE) are unknown. In this study, NZB/W F1 mice were utilized to investigate the effects of LF on SLE. Experiments reveal that LF significantly increases glutathione and 1,1-diphenyl-2-picryl-hydrazyl levels and significantly decreased malondialdehyde levels in both serum and liver in NZB/W F1 mice. LF also lowered matrix metalloproteinase-9 activity and liver inflammatory indices, such as aminotransferase and alanine aminotransferase. Notably, significantly decreased expression of fibrotic related molecules, including transforming growth factor (TGF)-ß1, tumor necrosis factor-α, interleukin-1ß, and TGF-ß1 receptor, were observed in the livers of NZB/W F1 mice that had been treated with LF. Significantly, suppressed Smad2/3 signaling, α-smooth muscle actin, and collagen deposition were also detected. These findings reveal that LF has beneficial effects on SLE by increasing antioxidant activities and ameliorating liver inflammation and fibrosis, suggesting the therapeutic effectiveness of LF against SLE.
Subject(s)
Antioxidants/analysis , Cholesterol, Dietary/administration & dosage , Liver Cirrhosis/drug therapy , Liver Cirrhosis/etiology , Lupus Erythematosus, Systemic/complications , Alanine Transaminase/analysis , Animals , Aspartate Aminotransferases/analysis , Cytokines/analysis , Glutathione/analysis , Glutathione/blood , Lactoferrin , Liver/chemistry , Liver/enzymology , Lupus Erythematosus, Systemic/drug therapy , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Inbred NZB , Signal Transduction/drug effects , Smad2 Protein , Smad3 ProteinABSTRACT
Systemic lupus erythematosus (SLE) is an autoimmune disorder with unknown etiology that impacts various organs including liver. Recently, human parvovirus B19 (B19) is recognized to exacerbate SLE. However, the effects of B19 on liver in SLE are still unclear. Herein we aimed to investigate the effects of B19 on liver in NZB/W F1 mice by injecting subcutaneously with PBS, recombinant B19 NS1, VP1u or VP2, respectively. Our experimental results revealed that B19 NS1 protein significantly enhanced the TGF-ß/Smad fibrotic signaling by increasing the expressions of TGF-ß, Smad2/3, phosphorylated Smad2/3, Smad4 and Sp1. The consequent fibrosis-related proteins, PAI-1 and α-SMA, were also significantly induced in livers of NZB/W F1 mice receiving B19 NS1 protein. Accordingly, markedly increased collagen deposition was also observed in livers of NZB/W F1 mice receiving B19 NS1 protein. However, no significant difference was observed in livers of NZB/W F1 mice receiving B19 VP1u or VP2 as compared to the controls. These findings indicate that B19 NS1 plays a crucial role in exacerbating liver fibrosis in NZB/W F1 mice through enhancing the TGF-â/Smad fibrotic signaling.
Subject(s)
Liver Cirrhosis/genetics , Liver Cirrhosis/virology , Liver/pathology , Parvovirus B19, Human/genetics , Parvovirus B19, Human/metabolism , Actins/genetics , Actins/metabolism , Animals , Collagen/genetics , Collagen/metabolism , ErbB Receptors/genetics , ErbB Receptors/metabolism , Female , Humans , Liver/metabolism , Liver/virology , Liver Cirrhosis/metabolism , Mice , Mice, Inbred NZB , Phosphorylation/genetics , Plasminogen Activator Inhibitor 1/genetics , Plasminogen Activator Inhibitor 1/metabolism , Signal Transduction/genetics , Smad Proteins/genetics , Smad Proteins/metabolism , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolismABSTRACT
Human parvovirus B19 (B19) has been associated with a variety of diseases. However, the influence of B19 viral proteins on hepatic injury in SLE is still obscure. To elucidate the effects of B19 viral proteins on livers in SLE, recombinant B19 NS1, VP1u or VP2 proteins were injected subcutaneously into NZB/W F1 mice, respectively. Significant expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were detected in NZB/W F1 mice receiving B19 NS1 as compared to those mice receiving PBS. Markedly hepatocyte disarray and lymphocyte infiltration were observed in livers from NZB/WF 1 mice receiving B19 NS1 as compared to those mice receiving PBS. Additionally, significant increases of Tumor Necrosis Factor -α (TNF-α), TNF-α receptor, IκB kinase -α (IKK-α), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IκB) and nuclear factor-kappa B (NF-κB) were detected in livers from NZB/W F1 mice receiving B19 NS1 as compared to those mice receiving PBS. Accordingly, significant increases of matrix metalloproteinase-9 (MMP9) and U-plasminogen activator (uPA) were also detected in livers from NZB/W F1 mice receiving B19 NS1 as compared to those mice receiving PBS. Contrarily, no significant variation on livers from NZB/W F1 mice receiving B19 VP1u or VP2 was observed as compared to those mice receiving PBS. These findings firstly demonstrated the aggravated effects of B19 NS1 but not VP1u or VP2 protein on hepatic injury and provide a clue in understanding the role of B19 NS1 on hepatic injury in SLE.
Subject(s)
Liver/virology , Lupus Erythematosus, Systemic/physiopathology , Parvovirus B19, Human , Viral Nonstructural Proteins/metabolism , Animals , Cyclooxygenase 2/metabolism , Endotoxins/metabolism , Female , Hepatocytes/cytology , I-kappa B Kinase/metabolism , I-kappa B Proteins/metabolism , Liver/enzymology , Lymphocytes/cytology , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Inbred NZB , Nitric Oxide Synthase Type II/metabolism , Open Reading Frames , Receptors, Tumor Necrosis Factor/metabolism , Recombinant Proteins/metabolism , Tumor Necrosis Factor-alpha/metabolism , Urokinase-Type Plasminogen Activator/metabolismABSTRACT
Both cell-mediated and humoral immunity have been widely investigated for the roles in pathogenesis of human parvovirus B19 (B19) infection. However, little is known about the effects of B19 infection on innate immunity. In the current study, expression of alpha-human neutrophil peptides (HNP) 1-3, alpha-human defensin (HD) 5, HD6, beta-human defensin (hBD)-1, hBD-3, toll-like receptor (TLR) 4, TLR5, TLR7 and TLR9 in B19-nonstructural protein (NS)-1 or B19-viral protein (VP)-2 transfected COS-7 cells was investigated by reverse transcription (RT)-PCR or by western blots. Significantly increased HNP1-3, HD5, HD6, hBD1 and hBD3 mRNA levels were detected at both 24 h and 20 days post-transfection in COS-7 cells transfected with pEGFP-NS1. In pEGFP-VP2-transfected COS-7 cells, significantly increased HNP1-3, HD5, HD6, hBD-1 and hBD-3 mRNA expression levels were observed on day 20, albeit only hBD3 mRNA increased significantly at 24 h post-transfection. Additionally, TLR4, TLR5 and TLR7 proteins decreased significantly in COS-7 cells transfected with pEGFP-NS1 or pEGFP-VP2 at 48 h but significantly increased on day 20. Notably, only TLR9 protein increased significantly in the cells transfected with pEGFP-NS1 on day 20. No significant variation of TLRs was observed in cells transfected with pEGFP-NS1K334E, a single substitution mutantation of B19-NS1 protein without original cytotoxicity, at both 48 h and on day 20. These novel findings revealed the different effects of B19-NS1 and VP2 on the stimulation of defensins and TLRs and could provide a clue in understanding the roles of B19-NS1 and VP2 on innate immunity.
Subject(s)
Defensins/genetics , Parvovirus B19, Human , Toll-Like Receptors/genetics , Animals , COS Cells , Chlorocebus aethiops , Immunity, Innate , RNA, Messenger/analysisABSTRACT
Human parvovirus B19 (B19) infection has been postulated to both myocardial injury and development of systemic lupus erythematosus (SLE). However, the influence of anti-B19-VP1u antibodies on cardiac disorders in SLE is still obscure. To elucidate the effects of anti-B19-VP1u IgG in SLE, passive transfer of PBS, normal rabbit IgG or rabbit anti-B19-VP1u IgG was injected intravenously into NZB/W F1 mice, respectively. Significant expression of IL-1ß, IL-6 and TNF-α were detected in NZB/W F1 mice receiving rabbit anti-B19-VP1u IgG. Markedly cardiomyocyte disarray and lymphocyte infiltration were observed in left ventricle of hearts from NZB/W F1 mice receiving rabbit anti-B19-VP1u IgG. Additionally, significant increases of matrix metalloproteinase-9 (MMP9) activity and protein expression were detected in left ventricle of hearts from NZB/W F1 mice receiving B19-VP1u IgG. Accordingly, significant increase of phosphorylated p-38 and NF-κB proteins were observed in left ventricle of hearts from NZB/W F1 mice receiving B19-VP1u IgG. However, no significant variation of cardiac atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), heart-type fatty acid-binding protein (h-FABP) and creatine kinase MB (CK-MB) were detected among all experimental groups. These findings firstly demonstrated the aggravated effects of anti-B19 VP1u IgG on cardiac injury by induction of inflammatory but not myocardial infarction-associated proteins through activation of phosphorylated p-38 and NF-κB signaling.
Subject(s)
Antibodies, Monoclonal/administration & dosage , Capsid Proteins/immunology , Heart Diseases/immunology , Heart Diseases/pathology , Lupus Erythematosus, Systemic/immunology , Myocytes, Cardiac/pathology , Parvovirus B19, Human/immunology , Animals , Antibodies, Monoclonal/immunology , Female , Heart , Heart Diseases/metabolism , Heart Ventricles/pathology , Immunization, Passive , Immunoblotting , Inflammation , Interleukin-1beta/biosynthesis , Interleukin-6/biosynthesis , Lupus Erythematosus, Systemic/pathology , Lymphotoxin-alpha/biosynthesis , Matrix Metalloproteinase 9/biosynthesis , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Inbred NZB , Myocardial Infarction/immunology , Myocardial Infarction/pathology , NF-kappa B/metabolism , Phosphorylation , Signal Transduction , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Numerous studies have implicated a connection between schizophrenia and autoimmune disorders. However, the precise relationship and underlying mechanism are still obscure. To further identify the association between autoimmune disorders and schizophrenia, the mRNA expressions of various cytokines and Toll-like receptors (TLRs) in monocytes are examined by using RT-PCR. Additionally, ELISA and zymography were performed to determine the anti-cardiolipin antibody (aCL) and MMP9 activity in serum form schizophrenic patients. Notably, significantly increased interleukin (IL)-6 and IL-10 mRNA were observed in schizophrenic patients, whereas significant reductions of TLR-3 and TLR-5 mRNA were detected. Moreover, significantly increased levels of aCL antibody and a higher frequency of positive-MMP9 activity were detected in serum from patients with schizophrenia. Meanwhile, no significant association was found between each of the medications and aCL activity. These findings demonstrated autoimmune-related phenomena in schizophrenic patients and further suggested a connection between schizophrenia and autoimmune disorders.
Subject(s)
Antibodies, Anticardiolipin/blood , Cytokines/metabolism , Schizophrenia/blood , Schizophrenia/immunology , Toll-Like Receptors/genetics , Adult , Analysis of Variance , Cytokines/genetics , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation/physiology , Humans , Male , Matrix Metalloproteinase 9/blood , Middle Aged , Monocytes/metabolism , RNA, Messenger/metabolism , Schizophrenia/pathology , Toll-Like Receptors/metabolismABSTRACT
BACKGROUND: Human parvovirus B19 (B19) is known to induce apoptosis that has been associated with a variety of autoimmune disorders. Although we have previously reported that B19 non-structural protein (NS1) induces mitochondrial-dependent apoptosis in COS-7 cells, the precise mechanism of B19-NS1 in developing autoimmunity is still obscure. METHODS: To further examine the effect of B19-NS1 in presence of autoantigens, COS-7 cells were transfected with pEGFP, pEGFP-B19-NS1 and pEGFP-NS1K334E, a mutant form of B19-NS1, and detected the expressions of autoantigens by various autoantibodies against Sm, U1 small nuclear ribonucleoprotein (U1-snRNP), SSA/Ro, SSB/La, Scl-70, Jo-1, Ku, and centromere protein (CENP) A/B by using Immunoblotting. RESULTS: Significantly increased apoptosis was detected in COS-7 cells transfected with pEGFP-B19-NS1 compared to those transfected with pEGFP. Meanwhile, the apoptotic 70 kDa U1-snRNP protein in COS-7 cells transfected with pEGFP-B19-NS1 is cleaved by caspase-3 and converted into a specific 40 kDa product, which were recognized by anti-U1-snRNP autoantibody. In contrast, significantly decreased apoptosis and cleaved 40 kDa product were observed in COS-7 cells transfected with pEGFP-NS1K334E compared to those transfected with pEGFP-B19-NS1. CONCLUSIONS: These findings suggested crucial association of B19-NS1 in development of autoimmunity by inducing apoptosis and specific cleavage of 70 kDa U1-snRNP.
Subject(s)
Autoantigens/metabolism , Parvovirus B19, Human/metabolism , Ribonucleoprotein, U1 Small Nuclear/immunology , Ribonucleoprotein, U1 Small Nuclear/metabolism , Viral Nonstructural Proteins/metabolism , Animals , Apoptosis/immunology , Autoimmune Diseases/etiology , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Base Sequence , COS Cells , Chlorocebus aethiops , DNA Primers/genetics , DNA, Viral/genetics , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Mutagenesis, Site-Directed , Parvoviridae Infections/etiology , Parvoviridae Infections/immunology , Parvoviridae Infections/pathology , Parvovirus B19, Human/genetics , Parvovirus B19, Human/pathogenicity , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Transfection , Viral Nonstructural Proteins/geneticsABSTRACT
BACKGROUND: Human parvovirus B19 (B19) infection has been identified as a trigger of antiphospholipid syndrome (APS). However, the precise role of B19-VP1 unique region (VP1u) in patients with antiphospholipid syndrome remains unclear. METHODS: IgM and IgG against B19-VP, and serum levels of antibodies directed against cardiolipin (CL), beta2-glycoprotein-I (beta2GPI) and phospholipid (PhL) were determined using ELISA in 45 APS patients. Humoral responses of anti-B19-VP1u were assessed by Western blot and B19 DNA was detected by nested PCR. Absorption experiments were performed using B19-VP1u protein to determine the binding specificity of antiphospholipid antibodies (aPL). RESULTS: One and 18 of 45 APS patients had detectable levels of anti-B19-VP IgM and anti-B19-VP IgG, indicating recent and past infection respectively. All serum samples from APS patients with diagnostic pattern DNA(-)/IgM(-)/IgG(+) had anti-B19-VP1u activity. APS patients with anti-B19-VP1u antibody had a 4-fold increased risk for recurrent vascular thrombosis compared with those without anti-B19-VP1u antibody. The binding inhibition of CL, beta2GPI, and PhL by absorption with B19-VP1u ranged from 31.4% to 91.1%, 0.8% to 59.8% and 20.2% to 72.1% respectively. Significantly higher inhibition to beta2GPI by B19-VP1u absorption was observed in APS patients with anti-B19-VP1u antibody than in those without anti-B19-VP1u antibody. CONCLUSIONS: We show a close association of B19 infection with aPL production and suggest B19-VP1u may be of pathogenetic importance in some patients with APS.
Subject(s)
Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/immunology , Capsid Proteins/chemistry , Capsid Proteins/immunology , Parvovirus B19, Human/immunology , Absorption , Adult , Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/diagnosis , DNA, Viral/blood , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoglobulin M/blood , Immunoglobulin M/immunology , MaleABSTRACT
BACKGROUND: Previous studies have reported the association between the development of NS1-specific IgG and arthropathy after the infection of human parvovirus B19 (B19). However, the role of anti-B19-NS1 IgG in RA is still unclear. This study investigated the role of anti-B19-NS1 antibody in patients with rheumatoid arthritis (RA). METHODS: B19-VP IgM and IgG antibodies, nested PCR, B19-NS1 IgM and IgG antibodies, and anti-cyclic citrullinated peptide (CCP) antibodies were assessed by ELISA and Western blot in this study. RESULTS: Significantly higher prevalence of B19-NS1 IgM and IgG antibodies in patients with recent B19 infection was observed as well as the higher prevalence of B19-NS1 IgM and IgG antibodies in RA patients with seronegative diagnostic patterns. However, no significant variation of both B19-NS1 IgM and IgG was detected in RA patients with different B19 diagnostic patterns. Additionally, significantly higher presence of anti-CCP IgG was observed in RA patients with B19-NS1 IgM. CONCLUSIONS: This study suggests the possibility of anti-B19-NS1 IgM as an indicator for RA diagnosis and indicates the suspense of the higher prevalence of anti-B19-NS1 antibody in RA patients with seronegative B19 diagnostic patterns. However, these results provide clues in understanding the association of anti-B19-NS1 antibody in RA patients.
Subject(s)
Antibodies, Viral/immunology , Arthritis, Rheumatoid/immunology , Parvoviridae Infections/immunology , Parvovirus B19, Human/immunology , Viral Nonstructural Proteins/immunology , Adolescent , Adult , Aged , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/complications , Female , Humans , Male , Middle Aged , Mutation/genetics , Parvoviridae Infections/blood , Parvoviridae Infections/complications , Parvoviridae Infections/diagnosis , Viral Nonstructural Proteins/genetics , Viral Nonstructural Proteins/metabolismABSTRACT
BACKGROUND: Activity of secreted phospholipase A (sPLA2) has been implicated in a wide range of cellular responses. However, little is known about the function of human parvovirus B19-VP1 unique region (VP1u) with sPLA2 activity on macrophage. METHODS: To investigate the roles of B19-VP1u in response to macrophage, phospholipase A2 activity, cell migration assay, phagocytosis activity, metalloproteinase assay, RT-PCR and immunoblotting were performed. RESULTS: In the present study, we report that migration, phagocytosis, IL-6, IL-1beta mRNA, and MMP9 activity are significantly increased in RAW264.7 cells by B19-VP1u protein with sPLA2 activity, but not by B19-VP1uD175A protein that is mutated and lacks sPLA2 activity. Additionally, significant increases of phosphorylated ERK1/2 and JNK proteins were detected in macrophages that were treated with B19-VP1u protein, but not when they were treated with B19-VP1uD175A protein. CONCLUSION: Taken together, our experimental results suggest that B19-VP1u with sPLA2 activity affects production of IL-6, IL-1beta mRNA, and MMP9 activity, possibly through the involvement of ERK1/2 and JNK signaling pathways. These findings could provide clues in understanding the role of B19-VP1u and its sPLA2 enzymatic activity in B19 infection and B19-related diseases.
Subject(s)
Macrophages/physiology , Parvovirus B19, Human/enzymology , Parvovirus B19, Human/immunology , Phospholipases A/metabolism , Animals , Cell Line , Cell Movement/physiology , Extracellular Signal-Regulated MAP Kinases/genetics , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Interleukin-6/genetics , Interleukin-6/metabolism , JNK Mitogen-Activated Protein Kinases/genetics , JNK Mitogen-Activated Protein Kinases/metabolism , Macrophages/cytology , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Mice , Parvovirus B19, Human/genetics , Phagocytosis/physiology , Phospholipases A/genetics , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolismABSTRACT
BACKGROUND: Human parvovirus B19 infection has been postulated to the anti-phospholipid syndrome (APS) in autoimmunity. However, the influence of anti-B19-VP1u antibody in autoimmune diseases is still obscure. METHODS: To elucidate the effect of anti-B19-VP1u antibodies in systemic lupus erythematosus (SLE), passive transfer of rabbit anti-B19-VP1u IgG was injected intravenously into NZB/W F1 mice. RESULTS: Significant reduction of platelet count and prolonged thrombocytopenia time were detected in anti-B19-VP1u IgG group as compared to other groups, whereas significant increases of anti-B19-VP1u, anti-phospholipid (APhL), and anti-double strand DNA (dsDNA) antibody binding activity were detected in anti-B19-VP1u group. Additionally, significant increases of matrix metalloproteinase-9 (MMP9) activity and protein expression were detected in B19-VP1u IgG group. Notably, phosphatidylinositol 3-phosphate kinase (PI3K) and phosphorylated extracellular signal-regulated kinase (ERK) proteins were involved in the induction of MMP9. CONCLUSION: These experimental results firstly demonstrated the aggravated effects of anti-B19-VP1u antibody in disease activity of SLE.